Prime Medicine (NYSE:PRME) Rating Lowered to Neutral at HC Wainwright
Prime Medicine (NYSE:PRME – Get Free Report) was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a report issued on Tuesday, MarketBeat.com reports. PRME has been the topic of several other reports. Wedbush restated an “outperform” rating and set a $13.00 target price (up from $12.00) on shares […]
Prime Medicine (NYSE:PRME – Get Free Report) was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a report issued on Tuesday, MarketBeat.com reports. PRME has been the topic of several other reports. Wedbush restated an “outperform” rating and set a $13.00 target price (up from $12.00) on shares […]
